Allogene Therapeutics

+$0.50 (+6.67%) Today
-$0.01 (-0.12%) As of 12:00 AM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALLO and other ETFs, options, and stocks.

About ALLO

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.

CEO
David D. Chang
Employees
310
Headquarters
South San Francisco, California
Founded
2017

ALLO Key Statistics

Market cap
1.15B
Price-Earnings ratio
—
Dividend yield
—
Average volume
1.57M
High today
$8.03
Low today
$7.41
Open price
$7.53
Volume
1.27M
52 Week high
$27.86
52 Week low
$6.43

ALLO Earnings

-$0.60
-$0.40
-$0.20
$0.00
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Estimated
— per share
Actual
Expected Aug 3, After Hours
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure